PGC-1α drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity

By sjmartinez • November 27, 2024

Varuzhanyan G, Chen CC, Freeland J, He T, Tran W, Song K, Wang L, Cheng D, Xu S, Dibernardo GA, Esedebe FN, Bhatia V, Han M, Abt ER, Park JW, Memarzadeh S, Shackelford DB, Lee JK, Graeber TG, Shirihai OS, Witte ON. PGC-1α drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity. Proc Natl Acad Sci U S A. 2024 Dec 3;121(49):e2416882121. doi: 10.1073/pnas.2416882121. Epub 2024 Nov 26. PMID: 39589879.

Tags: ASCL1, Endocrinology, Hematology/Oncology, Lung cancer, Oxidative phosphorylation, PGC-1a, prostate cancer, Publications, Pulmonary, Critical Care & Sleep Medicine

Related Posts

Oxidative stress-regulatory role of miR-10b-5p in the diabetic human cornea revealed through integrated multi-omics analysis

Zha D, Gamez J, Ebrahimi SM, Wang Y, Verma N, Poe AJ, White S, Shah R, Kramerov AA, Sawant OB, Santiskulvong C, Stotland AB, Wang[...]

The gut microbiome promotes mitochondrial respiration in the brain of a Parkinson’s disease mouse model

Morais LH, Stiles L, Freeman M, Oguienko AD, Hoang JD, Ji J, Jones J, Quan B, Devine J, Bois JS, Chou TF, Trinh J, Picard[...]

Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors

Zhu L, Cheung YM, Chiang C, Gallagher EJ, Hamnvik OR, Mammen J, Quandt Z, Jones R, McDunn J, Al-Bahadili H, Angell T, Bancos I, Betof[...]